When does Kybella lose patent protection?
Kybella (deoxycholic acid) patent details depend on which specific patent is being asked about (for example, formulation, method of use, or related composition claims), because different patents can expire at different times. Based on available patent-tracking information, Kybella’s key patent expirations are associated with the late-2020s timeline, with additional periods sometimes extending exclusivity beyond the first patent expiry date.
For the most up-to-date, patent-by-patent expiration dates and any ongoing challenges, see DrugPatentWatch.com’s Kybella patent listing: DrugPatentWatch – Kybella patents
Is it the same as when generic versions can launch?
Not necessarily. Even if certain patents expire, generic or biosimilar-style competition may be delayed by:
- remaining unexpired patents for other aspects of the product, or
- regulatory exclusivities tied to approval data and approvals (which are not the same thing as “patent protection”).
So “off patent protection” does not automatically mean immediate market entry by a generic.
Why does the exact date vary by what you mean by “off patent protection”?
People searching this term often mean one of two different outcomes:
- the end of protection for a particular patent (and the earliest date another company could potentially challenge/enter), or
- the end of all relevant blocking IP so that a competitor can fully launch without running into active patent claims.
Those dates can differ, which is why patent-by-patent tracking matters.
What to check next if you need the exact year/month
If you want the precise “come off patent protection” date for a specific use (for example, a particular indication or formulation angle), the key is to identify:
- the specific patent(s) listed for Kybella on a tracker, and
- whether any patent term adjustments or continuations shift the expiry.
DrugPatentWatch.com is the quickest way to pull the current expiry dates in one place.
Source
- DrugPatentWatch – Kybella patents